Mattia Sturlese

Dr. Mattia Sturlese

Department of Pharmaceutical and Pharmacological Sciences, University of Padova (UNIPD), Padua, Italy
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2022 in Journal of Chemical Information and Modeling
Verified
Journal Article
Open access
Matteo PavanMatteo Pavan
Matteo Pavan
SMSilvia Menin
Silvia Menin
DBDavide Bassani
Davide Bassani
Mattia SturleseMattia Sturlese
Mattia Sturlese
Stefano MoroStefano Moro
Stefano Moro
The prediction of ligand efficacy has long been linked to thermodynamic properties such as the equilibrium dissociation constant, which considers both the association and the dissociation rates of a defined protein-ligand complex. In the last 15 years, there has been a paradigm shift, with an increased interest in the determination of kinetic properties such as the drug-target residence time since they better correlate with ligand efficacy compared to other parameters. In this article, we present thermal titration molecular dynamics (TTMD), an alternative computational method that combines a series of molecular dynamics simulations performed at progressively increasing temperatures with a scoring function based on protein-ligand interaction fingerprints for the qualitative estimation of protein-ligand-binding stability. The protocol has been applied to four different pharmaceutically relevant test cases, including protein kinase CK1δ, protein kinase CK2, pyruvate dehydrogenase kinase 2, and SARS-CoV-2 main protease, on a variety of ligands with different sizes, structures, and experimentally determined affinity values. In all four cases, TTMD was successfully able to distinguish between high-affinity compounds (low nanomolar range) and low-affinity ones (micromolar), proving to be a useful screening tool for the prioritization of compounds in a drug discovery campaign.

14 April 2016 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
ACAlberto Cuzzolin
Alberto Cuzzolin
Mattia SturleseMattia Sturlese
Mattia Sturlese
GDGiuseppe Deganutti
Giuseppe Deganutti
Veronica SalmasoVeronica Salmaso
Veronica Salmaso
DSDavide Sabbadin
Davide Sabbadin
Stefano MoroStefano Moro
Stefano Moro

26 November 2024 in Cell Metabolism
Verified
Journal Article
Open access
GGGaia Gherardi
Gaia Gherardi
AWAnna Weiser
Anna Weiser
FBFlavien Bermont
Flavien Bermont
EMEugenia Migliavacca
Eugenia Migliavacca
BBBenjamin Brinon
Benjamin Brinon
UMUmberto De Marchi
Umberto De Marchi
Mitochondrial calcium (mtCa2+) uptake via the mitochondrial calcium uniporter (MCU) couples calcium homeostasis and energy metabolism. mtCa2+ uptake via MCU is rate-limiting for mitochondrial activation during muscle contraction, but its pathophysiological role and therapeutic application remain largely uncharacterized. By profiling human muscle biopsies, patient-derived myotubes, and preclinical models, we discovered a conserved downregulation of mitochondrial calcium uniporter regulator 1 (MCUR1) during skeletal muscle aging that associates with human sarcopenia and impairs mtCa2+ uptake and mitochondrial respiration. Through a screen of 5,000 bioactive molecules, we identify the natural polyphenol oleuropein as a specific MCU activator that stimulates mitochondrial respiration via mitochondrial calcium uptake 1 (MICU1) binding. Oleuropein activates mtCa2+ uptake and energy metabolism to enhance endurance and reduce fatigue in young and aged mice but not in muscle-specific MCU knockout (KO) mice. Our work demonstrates that impaired mtCa2+ uptake contributes to mitochondrial dysfunction during aging and establishes oleuropein as a novel food-derived molecule that specifically targets MCU to stimulate mitochondrial bioenergetics and muscle performance.

8 April 2014 in Nature Communications
Verified
Journal Article
Open access
PDF file
DGDmitry Gorbunov
Dmitry Gorbunov
Mattia SturleseMattia Sturlese
Mattia Sturlese
FNFlorian Nies
Florian Nies
MKMurielle Kluge
Murielle Kluge
MBMassimo Bellanda
Massimo Bellanda
DODominik Oliver
Dominik Oliver
Prestin (SLC26A5) is a member of the SLC26/SulP anion transporter family. Its unique quasi-piezoelectric mechanical activity generates fast cellular motility of cochlear outer hair cells, a key process underlying active amplification in the mammalian ear. Despite its established physiological role, it is essentially unknown how prestin can generate mechanical force, since structural information on SLC26/SulP proteins is lacking. Here we derive a structural model of prestin and related transporters by combining homology modelling, MD simulations and cysteine accessibility scanning. Prestin’s transmembrane core region is organized in a 7+7 inverted repeat architecture. The model suggests a central cavity as the substrate-binding site located midway of the anion permeation pathway, which is supported by experimental solute accessibility and mutational analysis. Anion binding to this site also controls the electromotile activity of prestin. The combined structural and functional data provide a framework for understanding electromotility and anion transport by SLC26 transporters.

1 April 2017 in Structure
Verified
Journal Article
Closed access
Veronica SalmasoVeronica Salmaso
Veronica Salmaso
Mattia SturleseMattia Sturlese
Mattia Sturlese
ACAlberto Cuzzolin
Alberto Cuzzolin
Stefano MoroStefano Moro
Stefano Moro

1 January 2021 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
MPMatteo Pavan
Matteo Pavan
GBGiovanni Bolcato
Giovanni Bolcato
DBDavide Bassani
Davide Bassani
Mattia SturleseMattia Sturlese
Mattia Sturlese
Stefano MoroStefano Moro
Stefano Moro
The chemical structure of PF-07321332, the first orally available Covid-19 clinical candidate, has recently been revealed by Pfizer. No information has been provided about the interaction pattern between PF-07321332 and its biomolecular counterpart, the SARS-CoV-2 main protease (Mpro). In the present work, we exploited Supervised Molecular Dynamics (SuMD) simulations to elucidate the key features that characterise the interaction between this drug candidate and the protease, emphasising similarities and differences with other structurally related inhibitors such as Boceprevir and PF-07304814. The structural insights provided by SuMD will hopefully be able to inspire the rational discovery of other potent and selective protease inhibitors.